(Yicai) Nov. 27 -- Commercial Aircraft Corporation of China has received a CNY44 billion (USD6.2 billion) capital injection from eight state-owned shareholders, nearly doubling its registered capital, to support mass production of the C919 jetliner.

Shanghai-based Comac’s registered capital has increased to CNY94.1 billion from CNY50.1 billion, according to corporate information provider Tianyancha.

Sinochem Holdings was the only shareholder to not participate in the capital raise, with the others contributing varying amounts. The State-owned Assets Supervision and Administration Commission topped the list at CNY25 billion, boosting its stake to 53.1 percent from 49.8 percent.

The C919 is China’s first independently designed single-aisle narrow-body passenger jet and is widely seen as the country’s answer to the Airbus A320 and Boeing 737 Max, the two planes that dominate the global single-aisle market.

The C919 was first delivered in December 2022 and completed its maiden commercial flight the following May. To date, 26 have been delivered. They operate on more than 30 routes and have carried over two million passengers.

As the C919 moves into mass production, increasing capacity has become a priority. Comac aims to raise annual production capacity to 150 aircraft by 2027 and 200 by 2029, according to a research note from Tianfeng Securities.

Comac is also advancing its wide‑body jet program. The upcoming C929 twin‑aisle aircraft is being developed as China’s first domestic wide‑body passenger plane. It has around 280 seats versus the C919's 150.

Comac’s other shareholders are Shanghai Guosheng Group, Aviation Industry Corporation of China, Aluminum Corporation of China, China Baowu Steel Group, China National Building Material Group, China Electronics Technology Group, and China Reform Holdings.

Editor: Emmi Laine